Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Journal of Hematology
Published in: International Journal of Hematology 4/2010

01-11-2010 | Letter to the Editor

Postremission gemtuzumab ozogamicin for elderly patients with acute myelogenous leukemia with favorable characteristics and comorbid conditions

Authors: Motoshi Ichikawa, Akira Hangaishi, Yasuhito Nannya, Mineo Kurokawa

Published in: International Journal of Hematology | Issue 4/2010

Login to get access

Excerpt

Older age predicts poor prognosis of acute myeloid leukemia (AML), while AML mainly affects elderly patients. Intensive chemotherapy targeted to achieve complete remission (CR) may improve survival of older patients with AML [1, 2]; however, optimal postremission therapy remains unclear, although relapses remain a major problem. An immunotoxin conjugate gemtuzumab ozogamicin (GO) can induce remission in relapsed AML, and successful postremission therapy with GO has been reported [3, 4]. …
Literature
1.
Löwenberg B, Ossenkoppele GJ, van Putten W, Schouten HC, Graux C, Ferrant A, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med. 2009;361:1235–48.CrossRefPubMed
2.
Fernandez HF, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med. 2009;361:1249–59.CrossRefPubMed
3.
Poloni A, Capelli D, Trappolini S, Costantini B, Montanari M, Gini G, et al. Low-dose gemtuzumab–ozogamicin as post-consolidation therapy in elderly patients with acute myeloid leukaemia: a pilot study. Br J Haematol. 2010;150:119–20.PubMed
4.
El Kinge AR, Hatoum HA, Mahfouz RA, Otrock ZK, Jabbour E, Kantarjian H, et al. Gemtuzumab ozogamicin is a promising post-remission therapy for acute myeloid leukemia. Leuk Res. 2009;33:565–6.CrossRefPubMed
5.
Löwenberg B, Beck J, Graux C, van Putten W, Schouten HC, Verdonck LF, et al. Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study. Blood. 2010;115:2586–91.CrossRefPubMed
Metadata
Title
Postremission gemtuzumab ozogamicin for elderly patients with acute myelogenous leukemia with favorable characteristics and comorbid conditions
Authors
Motoshi Ichikawa
Akira Hangaishi
Yasuhito Nannya
Mineo Kurokawa
Publication date
01-11-2010
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 4/2010
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-010-0711-9

Other articles of this Issue 4/2010

International Journal of Hematology 4/2010 Go to the issue

Case Report

Sustained improvement in cardiac function with persistent amyloid deposition in a patient with multiple myeloma-associated cardiac amyloidosis treated with bortezomib

Case Report

Coexistence of chronic myeloid leukemia and pulmonary plasmacytoma mimicking primary lung cancer

Case Report

Incidental carcinomas detected by PET/CT scans in patients with malignant lymphoma

Letter to the Editor

Bortezomib for post-allogeneic hematopoietic stem transplantation relapse and GVHD in multiple myeloma: a single institute experience

Case Report

Acute renal failure associated with systemic polyoma BK virus activation in a patient with peripheral T-cell lymphoma

Original Article

A nonradiation-containing, intermediate-dose methotrexate regimen for elderly patients with primary central nervous system lymphoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits